ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.3327A>C (p.Lys1109Asn)

gnomAD frequency: 0.00001  dbSNP: rs41293449
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031103 SCV000244339 benign Breast-ovarian cancer, familial, susceptibility to, 1 2015-08-10 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.0000307
Ambry Genetics RCV000162723 SCV000213185 benign Hereditary cancer-predisposing syndrome 2014-11-18 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Invitae RCV000205796 SCV000261249 benign Hereditary breast ovarian cancer syndrome 2024-01-19 criteria provided, single submitter clinical testing
Counsyl RCV000031103 SCV000488284 benign Breast-ovarian cancer, familial, susceptibility to, 1 2016-02-12 criteria provided, single submitter clinical testing
GeneDx RCV000586144 SCV000512300 likely benign not provided 2021-01-25 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 25589003, 15385441, 17924331, 21990134, 16518693, 19996028, 18375895, 12531920, 21203900, 22753008)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000586144 SCV000699012 likely benign not provided 2016-02-11 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000162723 SCV000903026 benign Hereditary cancer-predisposing syndrome 2016-04-27 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000586144 SCV002048619 likely benign not provided 2020-12-14 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV000162723 SCV002538199 likely benign Hereditary cancer-predisposing syndrome 2021-07-26 criteria provided, single submitter curation
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV003493418 SCV004242825 likely benign not specified 2024-02-06 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000586144 SCV004704196 likely benign not provided 2024-01-01 criteria provided, single submitter clinical testing BRCA1: BP1
Sharing Clinical Reports Project (SCRP) RCV000031103 SCV000053699 benign Breast-ovarian cancer, familial, susceptibility to, 1 2010-11-30 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000586144 SCV000591436 uncertain significance not provided no assertion criteria provided clinical testing The c.3327A>C / p.Lys1109Asn is a missense variant, located in exon 11 of BRCA1. It is listed in dbSNP database (rs-id=rs41293449) from a clinical source where no frequency information was provided; therefore no conclusions can be drawn for its population occurrence. The c.3327A_C variant is classified as “not pathogenic or of no clinical significance” by two studies (Easton_2007_17924331, Tavtigian_2008_18951461. Another variant in the same position and resulting in the same amino acid alteration (c.3327A>G, p.lys1109Asn) is also reported in LOVD and BIC databases with unknown pathogenicity. A variant classification study using in silico and probability based likelyhood pathogenicity assays also presents this variant to have an unclassified pathogenicity (Spurdle_2008_18375895, Lindor_2011_21990134). The Lys1109 residue is conserved across mammals and species and computational analyses, SIFT, suggest that this variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. Based on the above information, the pathogenicity of this variants cannot be determined, thus we tend to classify it as a variant of uncertain clinical significance (VUS).
BRCAlab, Lund University RCV000031103 SCV004244053 benign Breast-ovarian cancer, familial, susceptibility to, 1 2020-03-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.